25 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
7629809	140	Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues.	University of Illinois At Chicago
7678430	23	Cyclic peptides as selective tachykinin antagonists.	Merck Sharp and Dohme Research Laboratories
19746979	2	Allosteric functional switch of neurokinin A-mediated signaling at the neurokinin NK2 receptor: structural exploration.	Umr Uds/Cnrs 7200
8691422	25	2-Phenyl-4-quinolinecarboxamides: a novel class of potent and selective non-peptide competitive antagonists for the human neurokinin-3 receptor.	Smithkline Beecham
7515443	79	Design and synthesis of side-chain conformationally restricted phenylalanines and their use for structure-activity studies on tachykinin NK-1 receptor.	Universit£
8388471	28	Tetrapeptide tachykinin antagonists: synthesis and modulation of the physicochemical and pharmacological properties of a new series of partially cyclic analogs.	Institut De Recherches Servier
1331460	54	Conformationally constrained tachykinin analogues: potent and highly selective neurokinin NK-2 receptor agonists.	Glaxo Group Research
1851847	22	Imidazo[4,5-b]quinoxaline cyanines as neurokinin antagonists.	Rochester
20617791	70	Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines.	University of Arizona
	14	Pharmacological profile and chemical synthesis of SR 48968, a non-peptide antagonist of the neurokinin A (NK2) receptor	TBA
8759639	33	Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P.	Hebrew University of Jerusalem
7562907	33	New spiropiperidines as potent and selective non-peptide tachykinin NK2 receptor antagonists.	Glaxo Wellcome Medicines Research Centre
1694545	28	Potent and highly selective neurokinin antagonists.	Glaxo Group Research